AbbVie Inc. Decrease in Unrecognized Tax Benefits is Reasonably Possible
AbbVie Inc. (ABBV) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $40.00 million as of 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2025-02-14
- 2024-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $40.00M.
- 2024-09-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $58.00M.
- 2024-06-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $162.00M.
- 2024-03-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $162.00M.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible |
|---|---|
| 2024-12-31 | $40.00M 10-K · filed 2025-02-14 |
| 2024-09-30 | $58.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $162.00M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $162.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $476.00M 10-K · filed 2024-02-20 |
| 2023-09-30 | $620.00M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $603.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $110.00M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $162.00M 10-K · filed 2023-02-17 |
| 2022-09-30 | $141.00M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $145.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $244.00M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $225.00M 10-K · filed 2022-02-18 |
| 2021-09-30 | $258.00M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $116.00M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $116.00M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $68.00M 10-K · filed 2021-02-19 |
| 2020-09-30 | $138.00M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $156.00M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $50.00M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $54.00M 10-K · filed 2020-02-21 |
| 2019-09-30 | $193.00M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $41.00M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $311.00M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $486.00M 10-K · filed 2019-02-27 |
| 2018-09-30 | $550.00M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $272.00M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $38.00M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $31.00M 10-K · filed 2018-02-16 |
| 2017-09-30 | $246.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $233.00M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $231.00M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $201.00M 10-K · filed 2017-02-17 |
| 2016-09-30 | $12.00M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $12.00M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $15.00M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $15.00M 10-K · filed 2016-02-19 |
| 2015-09-30 | $22.00M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |